Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,525 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,876 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04510051 | CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children | recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06917885 | CUE-102 in Recurrent Glioblastoma | recruiting | Phase 1 | 18 | David Reardon, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04908709 |
| Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors |
| recruiting |
| N/A |
| 25 |
| Emory UniversityOTHER |
| 1 |
| Mar 4, 2026 |
| clinicaltrials |
| NCT05124236 | Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases(PREOP-2) | recruiting | N/A | 200 | Susanne RogersOTHER | 3 | Mar 4, 2026 | clinicaltrials |
| NCT06546631 | Investigating Mechanistic Predictors of Interpatient Variability and Temozolomide (TMZ) Induced Haematological Toxicity for Glioma Patients(Improve TMZ) | recruiting | — | 55 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05681195 | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | recruiting | Phase 2 | 15 | Baptist Health South FloridaOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447531 | T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas | recruiting | N/A | 15 | John M. BuattiOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT04425434 | Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma(GFARB12019) | recruiting | — | 3,000 | French Africa Pediatric Oncology GroupOTHER | 6 | Mar 2, 2026 | clinicaltrials |
| NCT05636540 | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma | recruiting | Early Phase 1 | 30 | Heather WachtelOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06377371 | Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE | recruiting | Phase 4 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06719440 | Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume(BELGICA) | recruiting | N/A | 347 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05740839 | High-Intensity Interval Exercise in Young Adult Survivors of Pediatric Brain Tumors: A Pilot Feasibility Study(HYPE) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07236840 | Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors(NEMO) | recruiting | — | 600 | Tata Memorial CentreOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07405372 | Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas | recruiting | — | 10 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06058988 | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07426848 | OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients(OTSMILE) | recruiting | N/A | 96 | Royal College of Surgeons, IrelandOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | recruiting | Phase 2 | 55 | Stephen Bagley, MD, MSCEOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06475235 | Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL | recruiting | Phase 1 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT06878469 | SIMPLIFication of Care Pathways for Patients With Rare Brain Tumors Through Artificial Intelligence(SIMPLIF-AI) | recruiting | N/A | 200 | Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416890 | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma | recruiting | Phase 2 | 24 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417072 | GenoDrugP 2025: Study on Three-dimensional Models Derived From Brain Tumors in Pediatric Patients | recruiting | N/A | 50 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417085 | MICRO-BRAIN 2024: Study on Pediatric Brain Tumors | recruiting | N/A | 100 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04278118 | Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study(HiPPI) | recruiting | N/A | 70 | Emory UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04765514 | Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients | recruiting | Phase 2 | 107 | AHS Cancer Control AlbertaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06222138 | Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma(EXOFIELDS) | recruiting | N/A | 80 | Institut Claudius RegaudOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT06442748 | Short Versus Long-term Levetiracetam in Brain Tumors(LIBRA) | recruiting | Phase 3 | 604 | Tata Memorial CentreOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT05957679 | MRE Evaluation for Spinal Cord Tumor Surgery: Stiffness and Adhesion Assessment | recruiting | N/A | 20 | Shengjing HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06955208 | 3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features | recruiting | N/A | 300 | Shengjing HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06132685 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | recruiting | Phase 2 | 200 | Emory UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06831552 | Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma(RISE in HR NBL) | recruiting | N/A | 84 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07399821 | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma(GLOW-FISH) | recruiting | Phase 1 / Phase 2 | 22 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04706910 | 18F-DOPA II - PET Imaging Optimization | recruiting | Phase 3 | 800 | University of AlbertaOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05890781 | Engineering Immune Organoids to Study Pediatric Cancer(IMMUNEORGANOID) | recruiting | N/A | 108 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07396896 | KETO-TUMOR: a Study on Brain Tumors and Central Obesity | recruiting | N/A | 30 | Meyer Children's Hospital IRCCSOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05139277 | Evaluation of the CONVIVO System | recruiting | N/A | 30 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05700721 | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06117930 | Study of Human Brain-Gut Axis and Gut Microbiome in Patients With Brain Lesions - Repository for Neuroscience Research | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma(SIB-DOPA) | recruiting | Phase 2 | 75 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653635 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study(ReciDOPA) | recruiting | Phase 2 | 54 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 5, 2026source: clinicaltrials